Nationwide assessment of human papillomavirus (HPV) genotypes in cancers: implications for prevention and monitoring impact of current and future (9-valent) HPV vaccines in the United States

Goodman, Marc

72 - Focused Plenary
Nationwide assessment of human papillomavirus (HPV) genotypes in cancers: implications for prevention and monitoring impact of current and future (9-valent) HPV vaccines in the United States

Sunday, March 23, 2014: 2:09 PM

Ballroom D (Tampa Convention Center)

M. T. Goodman¹, E. Unger², T. Thompson², C. F. Lynch³, M. Steinau², B. Hernandez⁴, C. Hopenhayn⁵, E. J. Wilkinson⁶, G. C. Copeland⁷ and M. Saraiya²
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Centers for Disease Control and Prevention, Atlanta, GA, ³University of Iowa, Iowa City, IA, ⁴University of Hawaii Cancer Center, Honolulu, HI, ⁵University of Kentucky, Lexington, KY, ⁶University of Florida College of Medicine, Gainesville, FL, ⁷Michigan Department of Community Health, Lansing, MI

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

72 - Focused Plenary
Nationwide assessment of human papillomavirus (HPV) genotypes in cancers: implications for prevention and monitoring impact of current and future (9-valent) HPV vaccines in the United States

72 - Focused Plenary Nationwide assessment of human papillomavirus (HPV) genotypes in cancers: implications for prevention and monitoring impact of current and future (9-valent) HPV vaccines in the United States

72 - Focused Plenary
Nationwide assessment of human papillomavirus (HPV) genotypes in cancers: implications for prevention and monitoring impact of current and future (9-valent) HPV vaccines in the United States